Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Authors: Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, De Merino, LuisLa Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, Verma, Sunil, Pivot, X. ^*, Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L.

Source: In Annals of Oncology October 2014 25(10):1979-1987

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Authors: Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L.

Source: ANNALS OF ONCOLOGY. 25(10):1979-1987

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN361642350&indx=1&recIds=ETOCRN361642350

Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer

Authors: Blum, J. L., Barrios, C. H., Feldman, N., Verma, S., McKenna, E. F., Lee, L. F., Scotto, N., Gralow, J.

Source: BREAST CANCER RESEARCH AND TREATMENT. 136(3):777-788

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN323265092&indx=1&recIds=ETOCRN323265092

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
European Perspectives: A Dialogue with the European Oncology Community

Authors: Martin, M., Makhson, A., Gligorov, J., Lichinitser, M., Lluch, A., Semiglazov, V., Scotto, N., Mitchell, L., Tjulandin, S.

Source: ONCOLOGIST -MIAMISBURG-. 17(4):469-475

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN311759217&indx=1&recIds=ETOCRN311759217

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

Authors: Blum, J. L., Kohles, J., McKenna, E., Scotto, N., Hu, S., Odom, D., Kaye, J. A., Glück, S.

Source: BREAST CANCER RESEARCH AND TREATMENT. 125(2):431-439

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN282876629&indx=1&recIds=ETOCRN282876629

445 PrefHer: a Clinical Trial to Evaluate Patient Preference for Trastuzumab Administered Subcutaneously or Intravenously in Patients with HER2-positive Early Breast Cancer
Abstract Book EBCC8 - European Breast Cancer Conference

Authors: Pivot, X., Knoop, A., Curigliano, G., Barrett-Lee, P., Lichinitser, M., Mueller, V., Camci, C., Gligorov, J., Scotto, N.

Source: EUROPEAN JOURNAL OF CANCER. 48(SUPP/1):S176-S176

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN308888850&indx=1&recIds=ETOCRN308888850

P272 Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results

Authors: O'Shaughnessy, J., Brownstein, C., Hörsch, S., Scotto, N.

Source: In The Breast 2011 20 Supplement 1:S65-S65

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.